Slide 1: MicroPort Scientific Corporation 2023 Annual Results
MicroPort Scientific Corporation 2023 Annual Results April 2024
Slide 2: Disclaimer
2023 Annual Results Disclaimer 08 April 2024 This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no pa
Slide 3: Contents
Contents 1 Company Highlights 2 Business Review 3 Financial Review 4 Outlook 5 Appendix – Financial Statements
Slide 4: Outstanding Performance Across All Business Segments
2023 Annual Results Outstanding Performance Across All Business Segments 08 April 2024 2023 Revenue Growth Newly obtained registration approvals Cardiovascular Neurovascular $147.2mn Int’l revenue 16.2%YOY ↑71.3%YOY $93.9mn Int’l revenue 21.6%YOY ↑44.6%YOY 44 NMPA2 CRM $207.0mn ↓ 1.0 %YOY Surgical r
Slide 5: Actively Pursuing Cost-effectiveness Strategies
2023 Annual Results Actively Pursuing Cost-effectiveness Strategies 08 April 2024 Significant cost control across key items Provision of impairment in 2023 22ppts Cost items Changes % R&D ↓ 10% expenses 50% R&D ratio 40% S&M ratio S&M ↑ 2% G&A ratio Expenses 39% 35% G&A 29% 21% expenses ↓19% 2022 20
Slide 6: Export Business Continue to Grow Rapidly
2023 Annual Results Export Business Continue to Grow Rapidly 08 April 2024 Export Business 54% YOY Revenue growth Cardiovascular Endovascular Structure Heart • 2023 revenue up 71.3% YOY (APAC +114%); • 2023 revenue up 51.2% YOY, innovative products • Implantation volume up 90% YOY overseas in • Glo
Slide 7: Contents
Contents 1 Company Highlights 2 Business Review 3 Financial Review 4 Outlook 5 Appendix – Financial Statements
Slide 8: Cardiovascular Business
2023 Annual Results Cardiovascular Business 08 April 2024 Business highlights • 2023 revenue $147.2mn, up 16.2% YOY, sales of access products increased by 101.0% Revenue YOY, primarily attribute to sales synergy with coronary stent category; +101.0% USD: million • Continuously improving hospital cov
Slide 9: Orthopedics Business
2023 Annual Results Orthopedics Business 08 April 2024 Non-China business • 2023 revenue $210.0mn, up 4.6% YOY, revenue growth disrupted by supply chain issue since 2Q23, thanks Revenue Breakdown by region to actively developing dual supplies, supply chain has gradually stabilized and returned to no
Slide 10: CRM Business
2023 Annual Results CRM Business 08 April 2024 Non-China business China business Revenue Revenue +25.7% Top 1 Chinese player 191.1 190.8 One of the 16.2 No. 1 13.1 ONLY 5 market share for China-made products multi-national players 2022 2023 2022 2023 • 2023 revenue $190.8mn, down 2.8% YOY, terminal
Slide 11: Endovascular Business
2023 Annual Results Endovascular Business 08 April 2024 Business highlights Product Pre-clinical Clinical Registration Castor® Branched Aortic Stent-Graft USD: million Key Financials1 ✓ Obtained NMPA approval System (Custom-Made) 2022 +32.2% 2023 Resuscitative Endovascular Balloon • Submitted for NM
Slide 12: Neurovascular Business
2023 Annual Results Neurovascular Business 08 April 2024 Business highlights Product Pre-clinical Clinical Registration Tubridge Plus® USD: million Key Financials Flow-diverting Stent • Submitted for NMPA review 2022 2023 HS Comaneci® • CE marked & FDA cleared +21.6% 64% • FDA Breakthrough Device De
Slide 13: Structural Heart Business
2023 Annual Results Structural Heart Business 08 April 2024 Business highlights Product Pre-clinical Clinical Registration USD: million Revenue Gross profit margin ✓ Obtained NMPA approval VitaFlow Liberty® 2022 • Approaching CE registration +33.0% +4ppts 2023 +58.9% VitaFlow® III • Submitted for NM
Slide 14: Surgical Robot Business
2023 Annual Results Surgical Robot Business 08 April 2024 Business highlights Product Pre-clinical Clinical Registration • 2023 revenue $11.0mn, up 258.4% YOY, recorded robust sales growth for all marketed Toumai® Laparoscopic ✓ Obtained NMPA approval products, achieved breakthrough in globalization
Slide 15: Contents
Contents 1 Company Highlights 2 Business Review 3 Financial Review 4 Outlook 5 Appendix – Financial Statements
Slide 16: Consolidated Financial Performance
2023 Annual Results Consolidated Financial Performance 08 April 2024 Revenue Gross profit margin USD: million +15.8% 950.7 59.7% 56.0% 840.8 2022 2023 2022 2023 Operating expenses Total net loss & net loss attributable to equity shareholders USD: million USD: million Net loss attributable to equity
Slide 17: Operating Expenses
2023 Annual Results Operating Expenses 08 April 2024 Sales & marketing expenses Administrative expenses R&D expenses USD: million USD: million USD: million 400.0 40.0% 60.0% 450.0 50.0% 500.0 49.9% 400.0 45.0% 350.0 35.0% 50.0% 39.0% 29.4% 350.0 35.2% 40.0% 300.0 30.0% 400.0 39.9% 35.0% 40.0% 300.0
Slide 18: Contents
Contents 1 Company Highlights 2 Business Review 3 Financial Review 4 Outlook 5 Appendix – Financial Statements
Slide 19: Appendix I - Consolidated Income Statement
2023 Annual Results Appendix I - Consolidated Income Statement 08 April 2024 USD'000 2023 2022 Var. Revenue 950,725 840,831 13.1% Cost of sales (418,627) (339,060) 23.5% Gross profit 532,098 501,771 6.0% Other net income 36,513 36,150 1.0% Research and development costs (379,428) (419,828) -9.6% Dis
Slide 20: Appendix II - Consolidated Balance Sheet
2023 Annual Results Appendix II - Consolidated Balance Sheet 08 April 2024 USD'000 31 Dec 2023 31 Dec 2022 Var. Non-current assets Investment properties 6,256 6,579 -5% Other property, plant and equipment 1,004,573 993,014 1% Intangible assets 234,435 223,683 5% Goodwill 149,393 262,829 -43% Equity-
Slide 21: Appendix II - Consolidated Balance Sheet
2023 Annual Results Appendix II - Consolidated Balance Sheet 08 April 2024 USD'000 31 Dec 2023 31 Dec 2022 Var. Non-current liablities Interest-bearing borrowings 508,330 336,689 51% Lease liabilities 85,327 124,373 -31% Deferred income 42,344 38,123 11% Convertible bonds 306,103 769,553 -60% Contra
Slide 22: Disclaimer
2023 Annual Results Disclaimer 08 April 2024 This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no pa